In yesterday’s Wall Street session, BeiGene Ltd. (NASDAQ:BGNE) shares traded at $266.75, down -0.84% from the previous session.
28 analysts cover BeiGene Ltd. (NASDAQ:BGNE), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $350.00 and a low of $108.14, we find $295.21. Given the previous closing price of $269.00, this indicates a potential upside of 9.74 percent. BGNE stock price is now 23.34% away from the 50-day moving average and 51.61% away from the 200-day moving average. The market capitalization of the company currently stands at $28.57B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 23. Brokers who have rated the stock have averaged $277.56 as their price target over the next twelve months.
With the price target of $308, Daiwa Securities recently initiated with Buy rating for BeiGene Ltd. (NASDAQ: BGNE). On October 13, 2022, SVB Leerink Upgraded its previous ‘Mkt Perform’ rating to ‘Outperform’ on the stock increasing its target price from $177 to quote $200, while ‘Guggenheim’ rates the stock as ‘Buy’.
In other news, Wang Xiaodong, Chair, Scientific Advisory Brd sold 5,000 shares of the company’s stock on Jan 12. The stock was sold for $1,302,585 at an average price of $260.52. Upon completion of the transaction, the Chair, Scientific Advisory Brd now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 11, Chair, Scientific Advisory Brd Wang Xiaodong sold 2,500 shares of the business’s stock. A total of $631,647 was realized by selling the stock at an average price of $252.66. Insiders disposed of 17,228 shares of company stock worth roughly $4.6 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BGNE stock. A new stake in BeiGene Ltd. shares was purchased by AVIDITY PARTNERS MANAGEMENT LP during the first quarter worth $35,211,000. TANG CAPITAL MANAGEMENT LLC invested $28,009,000 in shares of BGNE during the first quarter. In the first quarter, GREAT WEST LIFE ASSURANCE CO /CAN/ acquired a new stake in BeiGene Ltd. valued at approximately $18,621,000. CAPTION MANAGEMENT, LLC acquired a new stake in BGNE for approximately $7,469,000. ARTISAN PARTNERS LIMITED PARTNERSHIP purchased a new stake in BGNE valued at around $3,517,000 in the second quarter. In total, there are 394 active investors with 57.40% ownership of the company’s stock.
On Tuesday morning BeiGene Ltd. (NASDAQ: BGNE) stock kicked off with the opening price of $266.01. During the past 12 months, BeiGene Ltd. has had a low of $118.18 and a high of $280.62. As of last week, the company has a debt-to-equity ratio of 0.14, a current ratio of 4.10, and a quick ratio of 3.90. The fifty day moving average price for BGNE is $216.26 and a two-hundred day moving average price translates $175.95 for the stock.
The latest earnings results from BeiGene Ltd. (NASDAQ: BGNE) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$5.59, missing analysts’ expectations of -$4.88 by -0.71. This compares to -$4.72 EPS in the same period last year. The company reported revenue of $387.63 million for the quarter, compared to $206.44 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 87.77 percent. For the current quarter, analysts expect BGNE to generate $385.77M in revenue.
BeiGene Ltd.(BGNE) Company Profile
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
